Gilead Sciences Inc (GILD)

[north40000]

In November 2019, Dew Diligence posted the following on the BT Value board about a GILD/Amarin "collaboration":

"Quote:
…GILD added Vascepa to NASH trial…
An earlier article in streetinsider.com was guilty of suggesting that GILD had some kind of partnership with AMRN, so an updated article was posted to rebut this notion:

https://www.streetinsider.com/Analyst+Comments/Amarin+%28AMRN%29+Smacked+on+Bearish+Call%2C+But+Gilead+%28GILD%29+Adding+Vascepa+to+its+NASH+Combo+Raises+Eyebrows/16159446.html
Quote:
A recent posting at clinicaltrials.gov, pointed out by Raymond James' Gilead analyst Steven Seedhouse, showed that a cohort was added to the protocol that includes Amarin's Vascepa along with firsocostat (ACC inhibitor) and cilofexor (FXR agonist).

The analyst thinks Vascepa was added to compensate for the increase in TGs caused by firsocostat. He said this is similar to how statins compensate for LDL-C increase by FXR agonists.

Seedhouse said he is not aware of any formal collaboration between Amarin and Gilead, so he presumes Gilead is purchasing drug material."

I am trying to obtain any news of what has happened with respect to results from the added Vascepa mentioned in the above-quoted material. Comments from anyone with specific knowledge would be appreciated. Our portfolios contain both GILD and AMRN.

The FDA approved Vascepa for reducing the risk from various aspects of CVDs last December 2020.

See also:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155960148